SCHEMBL3856779

SCHEMBL3856779

O=C(O)c1cc(S(=O)(=O)O)c(F)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA3 P07451 2/20 0.54
CA4 P22748 2/20 0.54
CA6 P23280 2/20 0.54
CA5A P35218 2/20 0.54
CA7 P43166 2/20 0.54
CA9 Q16790 2/20 0.54
CA13 Q8N1Q1 2/20 0.54
CA14 Q9ULX7 2/20 0.54
CA5B Q9Y2D0 2/20 0.54
CISD1 Q9NZ45 2/20 0.54
ALDH1A1 P00352 4/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
EPHX2 P34913 1/20 0.46
ATM Q13315 1/20 0.44
TSHR P16473 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL397474 0.86 CA12 (0.54) CA12CA1CA2CA3CA4
SCHEMBL8574555 0.84 CA12 (0.53) CA12CA1CA2CA3CA4
SCHEMBL330135 0.84 CA12 (0.72) CA12CA1CA2CA3CA4
SCHEMBL13687164 0.84 POLB (0.42) CA12CA1CA2CA3CA4
SCHEMBL3522867 0.83 HSD17B10 (0.44) CA12CA1CA2CA3CA4
SCHEMBL29055167 0.83 CA12 (0.70) CA12CA1CA2CA3CA4
SCHEMBL13687080 0.81 POLB (0.41) CA12CA1CA2CA3CA4
SCHEMBL3522811 0.80 ATM (0.50) CA12CA1CA2CA3CA4
SCHEMBL11849578 0.79 CA12 (0.59) CA12CA1CA2CA3CA4
SCHEMBL20449207 0.79 CA12 (0.50) CA12CA1CA2CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589207-B2 Cyclohexyl compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2009-09-15 US disclosed
EP-1569647-B1 CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2008-08-20 EP disclosed
US-20060122166-A1 Cyclohexyl compounds as ccr5 antagonists SMITHKLINE BEECHAM CORPORATION 2006-06-08 US disclosed
EP-1569647-A2 CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS SmithKline Beecham Corporation (US) 2005-09-07 EP disclosed
WO-2004054581-A2 CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122166-A1 Cyclohexyl compounds as ccr5 antagonists CCR5, CCR1, CCR3 CA12 4846/4885CA1 4829/4885CA2 4195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.